(VIANEWS) – GREENVOLT (GVOLT.LS), NAVAMEDIC (NAVA.OL), PERNOD RICARD (RI.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. GREENVOLT (GVOLT.LS)
347.9% sales growth and 6.25% return on equity
Greenvolt – Energias Renováveis, S.A. operates in the renewable energy sector in Portugal, the United Kingdom, and internationally. The company operates through Residual Biomass; Development of Wind and Solar Utility-Scale; and Distributed Generation segments. It is involved in operation and development of biomass plants, as well as development of wind and solar photovoltaic plants in the European markets. The company was formerly known as Bioelétrica da Foz, S.A. and changed its name to Greenvolt – Energias Renováveis, S.A. Greenvolt – Energias Renováveis, S.A. was incorporated in 2002 and is headquartered in Porto, Portugal.
Earnings Per Share
As for profitability, GREENVOLT has a trailing twelve months EPS of €0.13.
PE Ratio
GREENVOLT has a trailing twelve months price to earnings ratio of 49.08. Meaning, the purchaser of the share is investing €49.08 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.25%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.1%, now sitting on 259.5M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
GREENVOLT’s EBITDA is 84.65.
Sales Growth
GREENVOLT’s sales growth is 269.3% for the current quarter and 347.9% for the next.
More news about GREENVOLT.
2. NAVAMEDIC (NAVA.OL)
9.6% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.79.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 21.51. Meaning, the purchaser of the share is investing kr21.51 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
Moving Average
NAVAMEDIC’s worth is under its 50-day moving average of kr38.73 and higher than its 200-day moving average of kr35.15.
Revenue Growth
Year-on-year quarterly revenue growth grew by 93.3%, now sitting on 440.93M for the twelve trailing months.
More news about NAVAMEDIC.
3. PERNOD RICARD (RI.PA)
7.9% sales growth and 14.84% return on equity
Pernod Ricard SA produces and sells wines and spirits worldwide. The company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 Pipers, Aberlour, Absolut, Absolut Elyx, Altos, ARARAT, Augier, Avion, Ballantine's, Becherovka, Beefeater, Blenders Pride, Brancott Estate, Campo Viejo, Ceder's, Chivas, Church Road, Clan Campbell, Del Maguey, George Wyndham, Green Spot, Havana Club, Imperial, Imperial Blue, Italicus, J.P. Wiser's, Jacob's Creek, Jameson, Jefferson's, Kahlúa, Kenwood, KI NO BI, Lillet, Long John, L'Orbe, Lot No. 40, Malfy, Malibu, Martell, Method & Madness, Midleton Very Rare, Minttu, Monkey 47, Mumm, Olmeca, Ostoya, Passport Scotch, Pastis 51, Pernod, Perrier-Jouët, Plymouth Gin, Powers, Rabbit Hole, Ramazzotti, Redbreast, Ricard, Royal Salute, Royal Stag, Scapa, Seagram's Gin, Secret Speyside, Smooth Ambler, Something Special, St Hugo, Stoneleigh, Suze, The Glenlivet, TX, Wyborowa, and Ysios. It also provides non-alcoholic beverages under the brands Ceder's, Suze Tonic 0%, Cinzano Spritz 0%, Pacific, Campo Viejo Sparkling 0%, and Jacob's Creek Unvined. The company was founded in 1805 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, PERNOD RICARD has a trailing twelve months EPS of €9.46.
PE Ratio
PERNOD RICARD has a trailing twelve months price to earnings ratio of 21.24. Meaning, the purchaser of the share is investing €21.24 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.84%.
Volume
Today’s last reported volume for PERNOD RICARD is 141879 which is 69.27% below its average volume of 461752.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.4%, now sitting on 11.86B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jul 5, 2023, the estimated forward annual dividend rate is 4.62 and the estimated forward annual dividend yield is 2.3%.
More news about PERNOD RICARD.
4. OENEO (SBT.PA)
6.7% sales growth and 12.71% return on equity
Oeneo SA operates in the wine industry worldwide. The company manufactures and sale of cork closures. It also provides solutions in wine making and spirits. Oeneo SA is headquartered in Bordeaux, France. Oeneo SA is a subsidiary of Caspar SAS.
Earnings Per Share
As for profitability, OENEO has a trailing twelve months EPS of €0.63.
PE Ratio
OENEO has a trailing twelve months price to earnings ratio of 22.62. Meaning, the purchaser of the share is investing €22.62 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.71%.
Moving Average
OENEO’s worth is higher than its 50-day moving average of €14.02 and under its 200-day moving average of €14.42.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 340.62M for the twelve trailing months.
More news about OENEO.
